Quebec scientist and scientific director of Canadian vaccine research network CANVAC, Rafick-Pierre S

A new study released by CytRx Corporation Wednesday shows great results in the fight against strains of HIV and AIDS.

The interim results from a Phase-One clinical trial indicating that a novel HIV DNA + protein vaccine was well tolerated, stimulated immune "T-cells" that potentially can attack AIDS virus-infected cells, and produced potent antibody responses with neutralizing activity against multiple HIV viral strains

Quebec scientist and scientific director of Canadian vaccine research network CANVAC, Rafick-Pierre S

The Centers of Disease Control and Prevention are guaranteeing the availability of as many as 97 million influenza shots in the U.S. market this upcoming flu season.

According to the CDC, along with the addition of GlaxoSmithKline, there are four companies providing vaccines to the United States

A new flu shot, Fluarix, earns The Food and Drug Administration's approval in a push to have more available flu vaccines after last year's unexpected shortage.

Fluarix is a flu shot made in Germany by a subsidiary of GlaxoSmithKline and is approved for use in adults 18 and older